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Abstract
The clinical features of corona virus disease 2019 (COVID-19) are variable, but the majority of patients experience mild flu-like symptoms. The 
cases of severe disease include complications such as progressive pneumonia, acute kidney injury (AKI), multi-organ failure, and even death. 
This paper explores the association between COVID-19 and its effect on multiple organ systems and how the subsequent treatment of this dis-
ease can itself  lead to morbidity and mortality. We present a case that emphasizes the life-threatening gastrointestinal complications associated 
with the treatment of AKI in a patient with COVID-19. We conclude that the patients whose treatment regimens utilize medical resins should 
be closely monitored for gastrointestinal complications so as to mitigate the known adverse effects associated with these drugs, such as colonic 
mucosal ulceration, perforation, or even death.
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Introduction
Corona virus disease 2019 (COVID-19) associated with the 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) virus was first described in late 2019 but has since 
disseminated across the globe leading to a worldwide pan-
demic. Millions of cases have been reported thus far, and the 
numbers continue to rise.
The clinical features of COVID-19 are variable; how-
ever, the initial clinical presentation of the disease is usually 
asymptomatic or mild. Symptoms include fever, dry cough, 
sore throat, rhinorrhea, headache, fatigue, shortness of 
breath, bone pain, loss of smell and taste, nausea, vomiting, 
and diarrhea (1–3). Even though COVID-19 leads to mild 
flu-like symptoms in the majority of those affected, some 
patients may experience severe disease with complications 
such as progressive pneumonia, acute respiratory distress 
syndrome, acute cardiac injury, multi-organ failure, and ulti-
mately death (2).
This paper explores the association between COVID-19 
and its effect on multiple organ systems and how the sub-
sequent treatment of this disease can lead to morbidity and 
mortality. We explore the indirect consequences of treatment 
in patients with COVID-19. Specifically, we present a case 
that emphasizes the life-threatening gastrointestinal compli-
cations associated with the treatment of acute kidney injury 
(AKI) in a patient with COVID-19.
Indirect consequences of COVID-19 treatment
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Discussion
The presentation of COVID-19 varies depending on the 
organs involved. The most frequent presenting symptoms 
of COVID-19 are fever (77.4–98.6%), cough (59.4–81.8%), 
fatigue (38.1–69.6%), dyspnea (3.2–55.0%), myalgia (11.1–
34.8%), sputum production (28.2–56.5%), and headache 
(6.5–33.9%) (4, 5). Additional symptoms such as sore throat, 
rhinorrhea, chest pain, hemoptysis, conjunctival congestion, 
nausea, vomiting, and diarrhea occurred less frequently (4).
Epidemiology
The transmission of SARS-CoV-2 occurs via droplets from 
coughing, sneezing, or direct contact, while several studies 
assert that the fecal-oral pathway may also be a potential 
route of transmission (4). The virus affects all age groups, 
but the median age for those infected by the virus is greater 
than 60 years (6).
Factors that contribute to disease severity include preexist-
ing comorbidities. Almost half  of all patients diagnosed with 
COVID-19 have one or more comorbidities such as diabetes 
mellitus, cardiovascular disease, hypertension, chronic lung 
disease, chronic kidney disease (CKD), immunocompromis-
ing conditions, severe obesity (body mass index ≥ 40), liver 
disease, and malignancy (4, 6). The most common comor-
bidities in deceased patients are: arterial hypertension (70%), 
diabetes mellitus (31.7%), CKD (23.1%), atrial fibrillation 
(22.5%), chronic obstructive pulmonary disease (COPD) 
(18.1%), the presence of an active cancer within the previous 
5 years (16.8%), ischemic heart disease (16%), and obesity 
10% (6).
The diverse presentations of COVID-19 relate to the organ 
systems affected by the virus, which include respiratory, 
hematopoietic/immune, cardiovascular, urinary, gastrointes-
tinal, reproductive, nervous, integumentary, and endocrine 
(7–11).
Pathophysiology
The pathogenicity of the SARS-CoV-2 virus begins with its 
entry into host cells. The main mechanism of infection lies 
in the high binding affinity of the virus with the angioten-
sin-converting enzyme 2 (ACE2) receptor (1, 4, 10, 12). The 
ACE2 protein is present in various human organs, including 
the lungs, heart, gastrointestinal tract, liver, kidney, spleen, 
lymph nodes, bone marrow, and brain (9–11, 13). In addi-
tion, SARS-CoV-2 relies on transmembrane protease serine 
2 for successful attachment and subsequent infection (1, 6, 
12, 14). The viral infection induces an immune response with 
excessive release of inflammatory cytokines and chemokines, 
which have the potential to cause acute respiratory distress 
and multiple organ failure (6, 9).
Case Presentation
A 37-year-old male with past medical history of asthma and 
hypertension presented to an outside hospital with respira-
tory distress and presumed asthma exacerbation. He was ini-
tially placed on high flow nasal cannula and steroids. Testing 
for SARS-CoV-2 was reportedly positive. Remdesivir was 
administered, and he was subsequently intubated and placed 
on mechanical ventilation due to worsening respiratory sta-
tus. Imaging reportedly showed patchy diffuse bilateral con-
solidative and ground-glass infiltrates. The patient’s white 
blood cell count was elevated, and he was placed on broad 
spectrum antibiotics. His outside hospital course was com-
plicated by AKI with increased creatinine and hyperkalemia 
for which he was given Kayexalate (sodium polystyrene sul-
fonate [SPS]). After approximately 10 days of hospitalization 
and worsening condition, he was transferred to the Univer-
sity of Mississippi Medical Center (UMMC) for a higher 
level of care.
On admission to our institution, Remdesivir was held due 
to renal failure, and antibiotics were discontinued as he had 
received an appropriate duration at the outside hospital. He was 
started on heparin infusion due to the hypercoagulable state 
(elevated D-dimer). He was transferred to the medical intensive 
care unit for acute hypoxic respiratory failure in the setting of 
COVID-19 pneumonia complicated by AKI. Lab results were 
notable for continued hyperkalemia and elevated phosphorus 
for which the patient was treated with Lokelma (sodium zirco-
nium cyclosilicate) and Renvela (sevelamer), respectively. Liver 
enzymes were also elevated (ALT 804 and AST 209).
After nearly 2 weeks of hospitalization at the UMMC, the 
patient’s hemoglobin began to drop and there was clinical 
concern for a gastrointestinal bleed. At this time, the patient 
did not have any abdominal pain but experienced one epi-
sode of non - bloody emesis for which a nasogastric tube was 
placed. Subsequently, he developed a distended abdomen 
and reported an episode of hematochezia, which prompted 
an abdominal X-ray that showed multiple dilated loops of 
small bowel with concern for pneumoperitoneum. Next, a 
computed tomography scan of the abdomen confirmed the 
pneumoperitoneum, and the patient was taken for explor-
atory laparotomy. Intraoperatively, bloody fluid was noted 
in the pelvis and a firm mass was palpated along the mid 
ascending colon, which was highly suggestive of colon can-
cer. A right hemicolectomy was performed.
The gross findings were significant for a single perforated 
ulcer in the ascending colon (3.2 × 2.6 × 0.4 cm) with mul-
tiple additional smaller ulcers ranging from 0.3 to 1.3 cm. 
Microscopic examination revealed a transmural ulcer associ-
ated with acute inflammation, hemorrhage, and necrosis. In 
addition, crystals with morphologic and tinctorial qualities 
consistent with Kayexalate and sevelamer were embedded 
within the fibrinopurulent exudate.
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treatment should be administered (21). Calcium gluconate 
acts within minutes to stabilize the cardiomyocytes (21). The 
subsequent administration of glucose and insulin, or beta- 
agonists, works to shift potassium into the cells (21). Finally, 
agents that remove potassium from the body are adminis-
tered. Furosemide stimulates potassium excretion via the 
renal tubules, effectively removing potassium through the 
urine; however, it is critical that patients have normal renal 
function to employ this method (21). Hemodialysis removes 
potassium through the blood and is the therapy of choice 
for life-threatening hyperkalemia in patients with compro-
mised renal function (21). Another treatment option includes 
exchange resins, which remove potassium through the gas-
trointestinal tract, see Table 1.
SPS, originally approved for medical use in 1958, is an 
ion exchange resin that exchanges sodium for ammonium, 
calcium, magnesium, and potassium, essentially increasing 
potassium excretion via feces (22). Taking into account the 
list of potentially severe adverse effects, mentioned in Table 2, 
the U.S. Food and Drug Administration (FDA) issued a 
“black box” warning for the use of SPS (26). The potential for 
severe adverse events associated with the use of SPS have led 
to the suggestion that other treatment strategies be utilized 
before exchange resins are considered (22, 26). This leaves cli-
nicians to weigh the risks and benefits of its use on a case by 
case basis (22). Initially, gastrointestinal mucosal injury was 
attributed to the sorbitol, which is commonly used in solution 
with the SPS; however, subsequent investigations showed that 
the resin itself is capable of causing injury as well (24, 27, 28).
In 2015, patiromer, a synthetic polymer consisting of 
non-absorbable spherical beads, was approved for use in the 
United States (22). With a similar mechanism of action to 
SPS, patiromer ultimately increases fecal potassium excre-
tion in exchange for calcium (22). Sodium Zirconium Cyclo-
silicate is a non – absorbable selective cation exchanger 
approved for use in 2018 (22). It possesses high selectivity for 
potassium and binds greater than nine times the amount of 
potassium as compared with SPS (22).
AKI in COVID-19
In addition to the respiratory system, the urinary system is 
affected in many patients with COVID-19. The postmortem 
analysis of kidney specimens shows histopathologic changes 
such as severe acute tubular necrosis (6, 8, 9). Researchers 
have suggested a high incidence of kidney injury in COVID-
19, with over 40% of cases presenting with proteinuria at the 
time of hospital admission (6, 8, 15, 16).
The incidence of AKI among COVID-19 patients varies 
from 0.5 to 36.6% and tends to occur more frequently in 
those with severe disease (6, 8, 9, 11, 16–19). Patients with 
a prior history of CKD are more likely to develop AKI, but 
even then, patients who developed AKI during the course of 
disease had a higher mortality rate, 5.3 times increased risk 
of death, as compared to those without AKI (6, 8, 18). The 
data from a meta-analysis of 26 studies suggested that the 
mortality of patients with COVID-19 who develop AKI may 
be 13 times higher than patients with COVID-19 who do not 
develop AKI (20).
Management of AKI in COVID-19
AKI is a common occurrence in COVID-19. Subsequent 
electrolyte disturbances, specifically hyperkalemia, associ-
ated with AKI is the most frequent renal complication with 
an incidence of 12.5% (11). As clinicians are able to recog-
nize renal involvement in COVID-19 and execute appro-
priate treatment strategies, the subsequent development of 
AKI may be mitigated, thus reducing morbidity and mortal-
ity (16). Two common treatment strategies used thus far in 
addressing the symptomatology associated with COVID-19 
are fluid resuscitation and ventilation (16). To date, there is 
no specific treatment for COVID-19-induced AKI (17).
Management of acute hyperkalemia depends on potas-
sium level, and the presence or absence of electrocardio-
gram (EKG) changes. If  EKG changes are present or if  
plasma potassium level is more than 6.5 mEq/L, emergent 




Treatment Adverse events (22–25)
Hyperkalemia Sodium polystyrene sulfonate 
(Kayexalate)
Abdominal pain, diarrhea or constipation, bowel ischemia, 
ulcerations, necrosis, pseudomembranes, and perforations
Patiromer Hypomagnesemia, hypokalemia, constipation
Sodium zirconium cyclosilicate Minor gastrointestinal symptoms, urinary tract infection, edema, 
hypokalemia
Hyperphosphatemia Sevelamer (Renagel, Renvela) Erosions, ulcerations, and pseudoinflammatory polyps
Indirect consequences of COVID-19 treatment
 Journal of Renal and Hepatic Disorders 2021;5(1): 6–13 9
In addition to potassium regulation, the kidney also plays 
a role in phosphate homeostasis. Accordingly, hyperphos-
phatemia contributes to morbidity associated with kidney 
dysfunction as well (29). Clinical manifestations of pro-
longed hyperphosphatemia consist of secondary hyperpara-
thyroidism and soft-tissue calcification, which may involve 
vessel walls leading to atherosclerosis (30).
To combat the effects of elevated phosphate, phosphate 
binders are used to decrease oral phosphate absorption (29). 
Sevelamer is a non - absorbable resin that binds phosphate 
in the GI tract and increases the excretion through the feces 
(29). This resin requires high doses in order to lower the 
phosphate to an appropriate level; consequently, this high 
level of resin is associated with adverse events (29).
Medical resins are used to remove excess electrolytes 
from the body. The documented side-effect profile for these 
medications include primarily gastrointestinal symptoms. 
The adverse events linked to the potassium-binding agent 
SPS (Kayexalate) include bowel ischemia, ulcerations, 
necrosis, pseudomembranes, and perforations. The newer 
potassium-binding agent, Lokelma (sodium zirconium cyclo-
silicate), has less adverse events including edema and hypo-
kalemia. The phosphate-binding agent, Renvela (sevelamer), 
has been associated with colonic mucosal erosions, ulcer-
ations, and pseudoinflammatory polyps. If  a patient who is 
treated with multiple resins experiences an adverse event, it 
becomes difficult to discern as to which offending agent is 
implicated in the mucosal injury.
These medical resins may be encountered in a colonic 
biopsy or resection specimen. Histologic identification may 
be difficult as the morphology may overlap between different 
resins (see Table 2 and Figures 1-8). However, once identified, 
these findings should be communicated to the clinical team.
Management of COVID-19
The treatment strategies for COVID-19 have been largely 
relegated to supportive care. Therapy has included empiric 
antibiotics, antiviral agents, corticosteroid treatments, intra-
venous immunoglobulin therapy, oxygen support, con-
tinuous renal replacement therapy, and extracorporeal 
membrane oxygenation (4).
Attempts to curtail the virus have been met with mixed 
results, but several antiviral drugs have been associated with 
less progression of the disease (7). One such drug, remdesivir, 
is a nucleotide analogue ribonucleic acid polymerase inhibi-
tor with broad-spectrum antiviral activity (4). In vitro stud-
ies have shown remdesivir and chloroquine to be effective in 
the control of SARS-CoV-2 infection (4, 31).
Treatment of  COVID-19 also has the potential to do 
harm. In addition to the virus injuring the hepatocytes, 
drug-induced hepatotoxicity can arise from medications 
used to treat patients with the illness. Hepatic enzymes 
are responsible for processing medications; therefore, the 
clinician must keep in mind the potential for drug-related 
hepatic toxicity. A multi-group clinical study evaluated liver 
injury in COVID-19 patients, showing that liver injury was 
related to disease severity (32). Patients with milder symp-
toms commonly showed transaminitis, while the degree of 
alanine aminotransferase and aspartate aminotransferase 
Table 2: Comparison of medical resin appearances in histologic sections.
Features Sodium polystyrene sulfonate Sevelamer
Brand name Kayexalate Renagel, Renvela
Mechanism of action Potassium-binding agent Phosphate-binding agent
Shape Rectangular Rectangular
Texture Fish scales Fish scales
Hematoxylin and eosin Purple Pink (center), yellow (edges)
Kinyoun stain Black Magenta
Source: Adapted from Gonzalez (28).
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Figure 1: Gross image of the right colon with a single, deep, 
cratered, perforated ulcer (3.2 × 2.6 × 0.4 cm) with multi-
ple additional smaller ulcers in the ascending colon (ranging 
from 0.3 to 1.3 cm).
Figure 2: Low power image of colonic mucosa with fibrino-
purulent exudate and crystals (Hematoxylin and eosin, 2× 
magnification).
Figure 3: Medium power image of colonic mucosa with fibri-
nopurulent exudate and crystals (Hematoxylin and eosin, 5× 
magnification).
Figure 4: Medium power image of fibrinopurulent exu-
date and Kayexalate crystal (Hematoxylin and eosin, 10× 
magnification).
Figure 5: Medium power image of fibrinopurulent exudate, 
with sevelamer (left) and Kayexalate (right) crystals (Hema-
toxylin and eosin, 10× magnification).
elevation was more pronounced in patients with severe dis-
ease (32).
Conclusion
The presentation of COVID-19 varies depending on the 
organs involved. The treatment of the extra pulmonary man-
ifestations is supportive and in some cases the therapy itself  
causes morbidity and mortality. AKI is just one of the many 
complications of COVID-19. The electrolyte disturbances 
associated with AKI can lead to severe consequences such as 
cardiac arrhythmias. The aggressive treatment of these elec-
trolyte imbalances is achieved in part by the use of medical 
resins. Patients who are being treated with these medical res-
ins should be closely monitored for gastrointestinal compli-
cations so as to mitigate the known adverse effects associated 
with these drugs.
Treatment regimens involving a combination of resins may 
be used for patients with kidney failure. The case we pres-
ent involves AKI in a patient with COVID-19 pneumonia. 
Indirect consequences of COVID-19 treatment
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Figure 6: High power images of fibrinopurulent exudate and embedded Kayexalate crystals with purple color and typical fish-
scale pattern (Hematoxylin and eosin, 20× magnification).
Figure 7: High power images of fibrinopurulent exudate and embedded sevelamer crystals with yellow color and fish-scale pat-
tern (Hematoxylin and eosin, 20× magnification). 
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Interestingly enough, the patient was being treated with rem-
desivir as well. Both COVID-19 and remdesivir have been 
documented to cause renal injury. The use of antivirals in 
combination with multiple resins in the treatment of COVID-
19 associated AKI has not been previously described and the 
potential for adverse events in these scenarios warrant fur-
ther investigation.
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